Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study

Introduction To compare the effect of dulaglutide and liraglutide on oxidative stress and endothelial function in patients with type 2 diabetes mellitus (T2DM). Methods Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue lira...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes therapy 2019-02, Vol.10 (1), p.215-228
Main Authors: Nagaike, Hiroe, Ohara, Makoto, Kohata, Yo, Hiromura, Munenori, Tomoyasu, Masako, Takada, Michiya, Yamamoto, Takeshi, Hayashi, Toshiyuki, Fukui, Tomoyasu, Hirano, Tsutomu
Format: Article
Language:English
Subjects:
Antidiabetics
Cardiology
Clinical trials
Comparative analysis
Development and progression
Diabetes
Drug therapy
Endocrinology
Glucose
Health aspects
Internal Medicine
Liraglutide
Medicine
Medicine & Public Health
Original Research
Oxidative stress
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction To compare the effect of dulaglutide and liraglutide on oxidative stress and endothelial function in patients with type 2 diabetes mellitus (T2DM). Methods Twenty-two patients with T2DM who received treatment with liraglutide for at least 12 weeks were randomized to either continue liraglutide or receive dulaglutide for 24 weeks. The primary end points were changes in the diacron-reactive oxygen metabolite (d-ROMs) test, as a marker of oxidative stress, and endothelial function, as determined by the reactive hyperemia index (RHI). The secondary end points were changes in body weight (BW), glucose variability, diabetes treatment satisfaction questionnaire (DTSQ) score, and eating behavior. Results There were no significant differences in changes in d-ROMs and logarithmic-scaled RHI (L-RHI) between the two groups after 24 weeks of treatment. Notably, the treatment with dulaglutide was superior to that with liraglutide in terms of mean glucose levels and mean amplitude of glycemic excursions following the 24-week treatment. However, in this regard, the outcome following the treatment with dulaglutide was maintained, whereas that with the treatment with liraglutide was aggravating. The DTSQ score for “convenience” improved in the dulaglutide group. No statistically significant changes in fasting plasma glucose, hemoglobin A1c, and BW were observed between the two groups. Conclusion We showed that once-weekly dulaglutide was comparable to once-daily liraglutide in terms of oxidative stress and endothelial function. Switching from liraglutide to dulaglutide improved convenience by decreasing the number of injections without deteriorating glucose metabolism. Trial Registration This trial was registered with the University Hospital Medical Information Network (UMIN no. 000034353) on 10 October 2018.
ISSN:1869-6953
1869-6961
DOI:10.1007/s13300-018-0560-8